Case Report
De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
Table 2
Summary of reported cases of ANCA vasculitis after SARS-CoV-2 vaccination.
| | Reference | Age/sex | Vaccine (doses) | ANCA | Organ involvement | Treatment | Outcome |
| | Anderegg et al. [6] | 81 y/female | mRNA-1273 Moderna (2) | PR3 | Kidney, lung | Steroids, CYC, TPE | Recovery | | Sekar et al. [7] | 52 y/male | mRNA-1273 Moderna (2) | PR3 | Kidney | Steroids, rituximab, CYC, hemodialysis | Chronic hemodialysis | | Shakoor et al. [8] | 78 y/female | BNT162b2 mRNA Pfizer-BioNTech (2) | MPO | Kidney | Steroids, rituximab | Recovery | | Villa et al. [9] | 63 y/male | AZD1222 Oxford-AstraZeneca (1) | MPO | Kindey, lung | Steroids, CYC | Recovery | | Patient 1 | 54 y/female | BNT162b2 mRNA Pfizer-BioNTech (2) | MPO | Kidney, lung | Steroids, rituximab | Recovery | | Patient 2 | 78 y/female | BNT162b2 mRNA Pfizer-BioNTech (2) | MPO | Kidney | Steroids, rituximab, hemodialysis | Chronic hemodialysis |
|
|
CYC, cyclophosphamide; TPE, therapeutic plasma exchange.
|
